日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Durvalumab combined with weekly carboplatin/paclitaxel as first-line treatment of patients with recurrent and/or metastatic HNSCC not eligible for cisplatin-based chemotherapies: results of the multicenter prospective study FRAIL-IMMUNE

Durvalumab联合每周一次的卡铂/紫杉醇作为一线治疗方案，用于不适合接受顺铂类化疗的复发性和/或转移性头颈部鳞状细胞癌（HNSCC）患者：多中心前瞻性研究FRAIL-IMMUNE的结果

期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2026.106946
Fayette, J; Cropet, C; Toullec, C; Burgy, M; Bruyas, A; Sire, C; Lagrange, A; Clatot, F; Vinches, M; Iacob, M; Martin, L; Kaminsky, M-C; Vansteene, D; Salas, S; Champagnac, A; Saintigny, P; Gautier, J; Pérol, D; Bourhis, J
细胞生物学
肿瘤
肿瘤免疫
多发性骨髓瘤
发表日期：2026
文献求助 收藏

Durvalumab and tremelimumab in combination with metronomic oral vinorelbine for recurrent advanced cervical cancer: an open-label phase I/II study

Durvalumab 和 tremelimumab 联合节拍式口服长春瑞滨治疗复发性晚期宫颈癌：一项开放标签 I/II 期研究

期刊:Journal for ImmunoTherapy of Cancer
影响因子:10.6
doi:10.1136/jitc-2024-010708
Frenel, Jean-Sébastien; Mathiot, Laurent; Cropet, Claire; Borcoman, Edith; Hervieu, Alice; Coquan, Elodie; De La Motte Rouge, Thibault; Saada-Bouzid, Esma; Sabatier, Renaud; Lavaud, Pernelle; Jimenez, Marta; Legrand, François; Le Saux, Olivia; Charafe, Emmanuelle; Gonçalves, Anthony
宫颈癌
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

MOVIE phase II trial of tremelimumab plus durvalumab combined with metronomic oral vinorelbine in patients with head and neck cancer

MOVIE II期临床试验，评估tremelimumab联合durvalumab和节拍式口服长春瑞滨治疗头颈癌患者的疗效

期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2025.105840
Borcoman, E; Hervieu, A; Cropet, C; Coquan, E; Guigay, J; Rolland, F; Bernadach, M; Charafe, E; Legrand, F; Dassé, E; Le Tourneau, C; Gonçalves, A
肿瘤
肿瘤免疫
头颈癌
发表日期：2025
文献求助 收藏

Tremelimumab plus durvalumab combined to metronomic oral vinorelbine: Results from the breast cancer cohort of the phase II MOVIE study

曲美利单抗联合度伐利尤单抗，并配合节拍式口服长春瑞滨：来自 II 期 MOVIE 研究乳腺癌队列的结果

期刊:Breast
影响因子:7.9
doi:10.1016/j.breast.2025.104549
De La Motte Rouge, T; Frenel, J-S; Cropet, C; Borcoman, E; Hervieu, A; Emile, G; Augereau, P; Charafe, E; Legrand, F; Dassé, E; Gonçalves, A
肿瘤
肿瘤免疫
乳腺癌
发表日期：2025
文献求助 收藏

Vaginal germ cell tumors: results from the international retrospective VAGIPED study

阴道生殖细胞肿瘤：来自国际回顾性VAGIPED研究的结果

期刊:British Journal of Cancer
影响因子:6.8
doi:10.1038/s41416-025-03201-3
Faure-Conter, Cécile; Lopes, Luiz Fernando; Gao, Yijin; Calaminus, Gabriele; Terenziani, Monica; De Pasquale, Maria Debora; Vojcek, Agnes; Velikonja, Orjana; Stefanowicz, Joanna; Jiang, Shayi; Yuan, Xiaojun; Han, Yali; López-Almaraz, Ricardo; Penn, Anthony; Stokes, Claire; Nuno, Michelle; Frazier, Lindsay; Billmire, Deborah F; Fresneau, Brice; Cropet, Claire
GIP
细胞生物学
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

Safety and quality of life with maintenance olaparib plus bevacizumab in older patients with ovarian cancer: subgroup analysis of PAOLA‑1/ENGOT-ov25

在老年卵巢癌患者中，使用奥拉帕尼联合贝伐单抗维持治疗的安全性和生活质量：PAOLA-1/ENGOT-ov25 亚组分析

期刊:Oncologist
影响因子:4.2
doi:10.1093/oncolo/oyae322
Montégut, Coline; Falandry, Claire; Cinieri, Saverio; Cropet, Claire; Montane, Laure; Rousseau, Frédérique; Joly, Florence; Moubarak, Malak; Mosconi, Anna M; Guerra-Alía, Eva M; Schauer, Christian; Fujiwara, Hiroyuki; Vergote, Ignace; Parma, Gabriella; Lindahl, Gabriel; Anota, Amélie; Canzler, Ulrich; Marmé, Frederik; Pujade-Lauraine, Eric; Ray-Coquard, Isabelle; Sabatier, Renaud
肿瘤
ENG
肿瘤免疫
卵巢癌
发表日期：2025
文献求助 收藏

Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial

在 III 期 PAOLA-1/ENGOT-ov25 试验中，根据临床风险，对新诊断的晚期卵巢癌患者进行奥拉帕尼联合贝伐单抗维持治疗，并更新无进展生存期和最终总生存期。

期刊:International Journal of Gynecological Cancer
影响因子:4.7
doi:10.1136/ijgc-2023-004995
Lorusso, Domenica; Mouret-Reynier, Marie-Ange; Harter, Philipp; Cropet, Claire; Caballero, Cristina; Wolfrum-Ristau, Pia; Satoh, Toyomi; Vergote, Ignace; Parma, Gabriella; Nøttrup, Trine J; Lebreton, Coriolan; Fasching, Peter A; Pisano, Carmela; Manso, Luis; Bourgeois, Hugues; Runnebaum, Ingo; Zamagni, Claudio; Hardy-Bessard, Anne-Claire; Schnelzer, Andreas; Fabbro, Michel; Schmalfeldt, Barbara; Berton, Dominique; Belau, Antje; Lotz, Jean-Pierre; Gropp-Meier, Martina; Gladieff, Laurence; Lück, Hans-Joachim; Abadie-Lacourtoisie, Sophie; Pujade-Lauraine, Eric; Ray-Coquard, Isabelle
肿瘤
ENG
肿瘤免疫
卵巢癌
发表日期：2024
文献求助 收藏

A multicentric, single arm, open-label, phase I/II study evaluating PSMA targeted radionuclide therapy in adult patients with metastatic clear cell renal cancer (PRadR)

一项多中心、单臂、开放标签的 I/II 期研究，评估 PSMA 靶向放射性核素疗法对转移性透明细胞肾癌成年患者的疗效 (PRadR)

期刊:BMC Cancer
影响因子:3.4
doi:10.1186/s12885-023-11702-8
Kryza, David; Vinceneux, Armelle; Bidaux, Anne-Sophie; Garin, Gwenaelle; Tatu, Delphine; Cropet, Claire; Badel, Jean-Noël; Perol, David; Giraudet, Anne-Laure
肿瘤
肾癌
肿瘤免疫
细胞生物学
发表日期：2024
文献求助 收藏

Long term activity of vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAF(V600)-mutated melanoma

维莫非尼在BRAF突变癌症中的长期疗效：ACSE针对除BRAF(V600)突变型黑色素瘤以外的晚期癌症的篮式研究

期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2023.102038
Blay, J Y; Cropet, C; Mansard, S; Loriot, Y; De La Fouchardière, C; Haroche, J; Topart, D; Tougeron, D; You, B; Italiano, A; Le Brun-Ly, V; Ferrero, J M; Penel, N; Fabbro, M; Troussard, X; Malka, D; Ray-Coquard, I; Leboulleux, S; Fléchon, A; Maubec, E; Charles, J; Dalle, S; Taieb, S; Garcia, G C T E; Mandache, A M; Colignon, N; Gavrel, M; Nowak, F; Hoog Labouret, N; Mahier Aït Oukhatar, C; Gomez-Roca, C
黑色素瘤
肿瘤
BRAF
肿瘤免疫
发表日期：2023
文献求助 收藏

MOVIE: a phase I, open-label, multicenter study to evaluate the safety and tolerability of metronomic vinorelbine combined with durvalumab plus tremelimumab in patients with advanced solid tumors

MOVIE：一项 I 期、开放标签、多中心研究，旨在评估节拍式长春瑞滨联合度伐利尤单抗和曲美木单抗治疗晚期实体瘤患者的安全性和耐受性。

期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2022.100646
Vicier, C; Isambert, N; Cropet, C; Hamimed, M; Osanno, L; Legrand, F; de La Motte Rouge, T; Ciccolini, J; Gonçalves, A
发表日期：2022
文献求助 收藏